Supplementary Table 5. Incidence rates and HR for primary composite outcome and each outcome among patients with definite spasm

Variable	No.	Event (%)	Person-month	Incidence rate	95% CI	p value[a]	HR[b]	95% CI	p value[b]
Composite outcome						0.1218			
Diltiazem	479	28 (5.85)	11,747	2.38	1.65–3.45		Reference		
Amlodipine	66	2 (3.0)	1,268	1.58	0.39–6.31		0.55	0.13–2.30	0.411
Nifedipine	52	7 (13.46)	1,341	5.22	2.49–10.95		2.30	1.00–5.26	0.049
Benidipine	24	1 (4.17)	895	1.12	0.16–7.93		0.67	0.09–4.93	0.695
Arrhythmia						0.5591			
Diltiazem	479	10 (2.09)	12,335	0.81	0.44–1.51		Reference		
Amlodipine	66	0	1,303	0.00	-		-		
Nifedipine	52	2 (3.85)	1,489	1.34	0.34–5.37		1.73	0.38–7.91	0.478
Benidipine	24	1 (4.17)	895	1.12	0.16–7.93		1.78	0.23–13.95	0.581
ACS						0.3465			
Diltiazem	479	20 (4.18)	12,216	1.64	1.06–2.54		Reference		
Amlodipine	66	1 (1.52)	1,307	0.77	0.11–5.43		0.46	0.06–3.44	0.451
Nifedipine	52	4 (7.69)	1,498	2.67	1.00–7.12		1.61	0.55–4.73	0.383
Benidipine	24	0	948	0.00	-		-		
Death						0.4358			
Diltiazem	479	2 (0.42)	12,549	0.16	0.04–0.64		Reference		
Amlodipine	66	1 (1.52)	1,326	0.75	0.11–5.35		4.17	0.38–46.02	0.244
Nifedipine	52	1 (1.92)	1,549	0.65	0.09–4.58		4.22	0.38–46.55	0.240
Benidipine	24	0	948	0.00	-		-		

HR, hazard ratio; CI, confidence interval; ACS, acute coronary syndrome.

[a]p value by log rank test.

[b]p value by univariate Cox proportional hazard regression.